Kyushu Corp: Two new products from subsidiaries have been added to the 2026 National Essential Medicines List.

Kyushu Communication announced that two new varieties of its holding subsidiary have been added to the "National Essential Medicine List", including the telmisartan tablets of Beijing Jingfeng Pharmaceutical Group Co., Ltd. and the terbinafine hydrochloride cream of its wholly-owned subsidiary Beijing Jingfeng Pharmaceutical Co., Ltd. This list will be implemented starting from September 1, 2026. The addition to the list will help expand the market for these products, but the sales of drugs are influenced by multiple factors, leading to uncertainties.